AstraZeneca has announced a $3.5 billion capital investment in the US with the aim of expanding its research and production infrastructure in the country by the end of 2026. This investment includes a contribution of 2 billion dollars that will allow the creation of more than a thousand highly qualified jobs., thus promoting the growth of the US economy.
AstraZeneca Jobs: Boosting Innovation and Economic Growth in the US
AstraZeneca's expansion into the United States includes the Opening of several research and production centres at several key locations, including a state-of-the-art research and development (R&D) center in Kendall Square, Cambridge, Massachusetts.
This expansion reflects the innovation and growth of AstraZeneca employment. It also demonstrates commitment to developing advanced capabilities in strategic sectors.»
«In addition, the company will build a state-of-the-art manufacturing facility in Maryland. It will strengthen its cell therapy capabilities on both coasts. It will develop a specialized plant in Texas.
Pascal Soriot, CEO of AstraZeneca, highlighted the importance of this investment in the context of the American economy and talent. According to Soriot, this multi-billion dollar commitment reflects the attractiveness of the US business environment, as well as the quality of the talent and the innovation capabilities of the country.
According to the company, these investments in the US are part of the growth strategy towards its «Ambition 2030», a plan that seeks to reach $80 billion in total revenue by 2030, a goal set in May of this year. Expansion in the US is essential to this strategy, given that the country represents AstraZeneca's largest market, generating 441% of its total revenue.
AstraZeneca has been expanding its global investments in North America, not only with significant projects in the United States but also in Canada. Recently, the company announced a investment of CAD$820 million in Ontario. This investment will strengthen research and development of treatments for cancer and rare disorders.
AstraZeneca in the US
AstraZeneca currently has approximately 17,800 employees in the U.S., spread across 17 research, manufacturing and commercial sites in 12 states. This robust presence underscores the company's commitment to innovation and development in one of the world's largest healthcare markets.
AstraZeneca's expansion in the US underlines its long-term strategy towards 'Ambition 2030'. It involves significant investment and job creation. This initiative seeks not only to increase revenues and presence in its main market. It also promotes professional growth by offering thousands of qualified jobs in research and production.
